80 results
Page 2 of 4
8-K
EX-99.1
ip2 4bwr8
8 Aug 22
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
4:32pm
8-K
EX-99.1
f135b jb5o
27 Jun 22
Entry into a Material Definitive Agreement
7:31pm
8-K
3fro4 6c03lj0
27 Jun 22
Entry into a Material Definitive Agreement
7:31pm
8-K
EX-99.1
fwhquizz5t60w7dd
16 Jun 22
Other Events
7:00am
8-K
EX-99.1
a97f d4gomsuokl
9 May 22
Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones
4:31pm
POS AM
sdtgzu18matsy142uypd
28 Feb 22
Prospectus update (post-effective amendment)
5:46pm
8-K
EX-99.1
gdglu
28 Feb 22
Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones
4:36pm
POSASR
tjaz53svh u8zd6css6e
28 Feb 22
Automatic shelf registration (post-effective amendment)
4:16pm
8-K
EX-99.1
ziz4frm
10 Jan 22
Regulation FD Disclosure
7:01am
8-K
EX-99.1
qij80gyjiae87o we9
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
8-K
EX-99.1
c270i0nldyrra6b
10 Nov 21
Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones
7:03am
8-K
EX-99.1
bs9 3bhvju
9 Aug 21
Business Highlights and Anticipated Second Half 2021 Milestones
7:01am